We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.
- Authors
Tsukasaki, Kunihiro; Utsunomiya, Atae; Fukuda, Haruhiko; Shibata, Taro; Fukushima, Takuya; Takatsuka, Yoshifusa; Ikeda, Shuichi; Masuda, Masato; Nagoshi, Haruhisa; Ueda, Ryuzo; Tamura, Kazuo; Sano, Masayuki; Momita, Saburo; Yamaguchi, Kazunari; Kawano, Fumio; Hanada, Shuichi; Tobinai, Kensei; Shimoyama, Masanori; Hotta, Tomomitsu; Tomonaga, Masao; Japan Clinical Oncology Group Study JCOG9801
- Abstract
Our previous phase II trial for treating human T-lymphotropic virus type I-associated adult T-cell leukemia-lymphoma (ATLL) with vincristine, cyclophosphamide, doxorubicin, and prednisone (VCAP), doxorubicin, ranimustine, and prednisone (AMP), and vindesine, etoposide, carboplatin, and prednisone (VECP) showed promising results. To test the superiority of VCAP-AMP-VECP over biweekly cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), we conducted a randomized controlled trial exclusively for ATLL.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Vol 25, Issue 34, p5458
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2007.11.9958